Subject Index

A
Absorbable vascular grafts, 197-217
Acellular vascular matrix, 219-235
Aneurysm, 58, 98 See also Failure, vascular grafts
Animal experimental models
baboon,
endothelial cell seeding, 39
graft surface modification, 145-147
dog,
acelluar vascular matrix, 226-235
carotid arteries, 219-235
collagen grafts, 299
endothelial cell seeding, 33-43, 190-195
replamineform small caliber grafts, 60-67
sterility, synthetic grafts, 236-249
pig,
vascular graft evaluation, various materials, 169-178
rabbit,
biodegradable vascular grafts, 200
polyglycolic acid prostheses, 200
Animal origin grafts,
FDA regulation of, 5-6
Antithrombotic drugs See Drugs, antithrombotic
Aortic grafts, 22, 203-214
Applicability of vascular grafts, 278-283, 279 (table)
Arterial surgery See Surgery, vascular
Arteries, 33-43
axillary,
bypass grafts, 27, 29
carotid,
use as vascular grafts, 113, 219-235
coronary,
bypass grafts, 44-49
femoral,
bypass grafts, 25-32,
life table patency, 22 (table)
internal mammary,
use as vascular grafts, 45-46
popliteal,
bypass grafts, 26, 27
Arteriography, 54, 57
Aspirin, 48-49, 192-194, 230
ASTM Committee F-4, Medical Surgical Materials and Devices, 257-262
ASTM Standards
D 276: 77
D 638: 115
D 671: 117-118
D 1059: 77
D 2256: 77
D 3786–80: 116
ASTM Subcommittee F04.04, Cardiovascular Implants and Materials, 262–263

B
Bacteria, 14, 236–249 See also Pyrogens; Sterility
Ball Burst Test
ASTM Standard D 3787–80a: 116
Basement membrane, 219–235
Bench testing
biological vascular grafts, 111–113
Dacron® grafts, 108–121
polytetrafluoroethylene grafts, 108–121
Biocompatibility
graft testing in various species, 169–249
Biodegradable vascular grafts, 197–217
Bioelectric polyurethane See Polyurethane, bioelectric
Biomaterial surface modification, 137–155
Bioprosthetic vascular grafts, 95–107
Blood compatibility, various materials, 172
Blood flow in vascular grafts, 146–154, 230 (table) See also Patency
Burst testing, 93, 116, 203
polytetrafluoroethylene, 92 (table)
Bypass grafts
axillary artery, 27, 29
coronary artery, 44–49
distal, 28–29, 52
extraanatomic, 26–31
femoral artery, 22 (table), 25–32
peroneal artery, 52–53
popliteal artery, 25–32, 52
tibial artery, 52–53

C
Calcification, vascular grafts, 174 (table)
Calorimeter, 87–89
Carbodiimide stabilizer, 226–235
Cardiac surgery See Surgery, cardiac
Cardiovascular devices
history of regulation, 253–277
Cell differentiation, 199–217
Cell migration, 197–217
Cell proliferation, 197–217
Cells,
endothelial See also Endothelialization
in absorbable polymeric grafts, 199–217
biochemistry of, 190
enzymatic harvest of, 189–196
use in seeding of grafts, 33–43, 189–196
smooth muscle cell interaction, 199
macrophages, 186, 199–217
myofibroblasts, 199–215
platelets, 38–39, 173
smooth muscle, 199
various cells, 157 (diagram)
Collagen
distribution in Dacron grafts, 184 (table)
effect on healing, 180–188
quantitative analysis of, 180–188
small caliber grafts, 293–304
Contact angle measurement, 100
biosynthetic data plot, 103
Contamination, vascular grafts, 245
"Critical surface tension"
biosynthetic grafts, 54, 100–102
Cross-linking reagents See Carbodiimide stabilizer; Glutaraldehyde stabilizer
Cyclooxygenase inhibitors, 192–194
Dacron vascular grafts
  collagen in, 180–188
  comparison
    in vitro vs animal/human testing
    of various types, 16–24
    to veinous grafts, 13–14
    compound materials, 211–213
    crimped vs noncrimped, 16–24
    endurance of, 16–24, 108–121
    fabrication of, 71–79
    FDA regulation of, 6–7
    fibrinogen adsorption, 143–145, 172–175
    history of development, 11–15, 17–18
    implantation in rabbit aorta, 203–214
    knitted vs woven, 16–24
    microanatomy of, 16–24
    platelet deposition, 172–175
    retrieved human grafts, 180–188
    seeding of, 37–39, 189–196
    spinning of yarn for, 73 (diagram)
    surface modification of, 137–155
    testing of, 80–81, 108–121
Detergents
  acellular matrix preparation, 226
Development of vascular grafts, 11–16
Device performance See Durability;
  Performance, vascular grafts
Diameter, grafts See Small caliber
  grafts
Differential scanning calorimeter, 87–89
Dipyridamole, 48, 192–195
Discharge treatment
  gas, 137
  plasma, 137
Doppler ultrasonic flowmeter, 146, 150
Drugs, antithrombotic, 48, 49 (tables)
aspirin, 48–49, 192–194, 230
  dipyridamole, 48, 192–194
  ibuprofen, 192–194
  U-53,059, 192–194
  U-63557A, 192–194
  Warfarin, 48–49
Durability,
  biological grafts, 111–113
  Dacron grafts, 16–24, 108–121
  polytetrafluoroethylene grafts, 108–121
Elasticity
  biosynthetic grafts, 97
Electroosmosis, 292–293
Embolus formation See Thrombus/
  embolus formation
Endothelialization See also Cells, endo-
  thelial
  acellular matrix grafts, dog, 232–235
  animal vs human, 14
  in bioelectric polyurethane grafts, 61
  carotid artery grafts, dog, 219–235
  Dacron grafts,
    dog, 189–196
    man, 18
  drugs and, 189–196
  polyglycolic acid grafts, 200–202
  review, synthetic grafts in dog/
    baboon experimental models,
    33–43
  in silicone rubber grafts, 61
  vascular grafts, man, 171, 173
    (table), 174
Endothelium, 33–43
Endotoxins, 242–245
Endurance See Durability
Evaluation
  retrieved vascular grafts, 161–164
Extraanatomic bypass, 26–31
Extremities See Limbs

**F**

Fabrication, vascular grafts, 71–79
  history of, 18–19
  replamineform, 51, 85–102
  warp knitting, 74–78
  weft knitting, 74–78
Failure, vascular grafts, 14, 98–99, 262–277, 279–280
Fatigue tests
  ASTM Standard D 671: 117–119
FDA See Food and Drug Administration
Fibrinogen adsorption, 143–145, 173
  (table)
Fibrohistiocystic tissue ingrowth, 63–66
Flex tester, 120 (diagram)
Fluoropolymer coatings, 137–155
Food and Drug Administration
  1976 Medical Device Amendment, 284–289
  performance standards development, 284–289
  regulations, 5–9, 284–289
Formaldehyde
  preservation retrieved grafts, 163
  (table)

**G**

Gas discharge treatment, 137
Glutaraldehyde stabilizer
  in biosynthetic vascular grafts, 99
  in carotid artery grafts, 226–235
  development of, 296–297
  preservation of retrieved grafts, 163
  (table)
  in umbilical cord vein grafts, 50–59
Gore-Tex See Polytetrafluoroethylene, expanded
Growth factors, 199, 209

**H**

Healing
  human grafts, 11–15, 180–188, 261, 267–268, 270
Hemocompatibility
  graft testing in various species, 169–178
Heparin, 226–228
History, vascular grafts
  development, 11–15, 83–84, 253–277
  legislation, 253–277
Host tissue, 99–100

**I**

Ibuprofen, 192–195
Infection, 58, 236–249
Inflammatory reaction
  Dacron grafts, 186, 204
  polyglycolic acid grafts, 201
International Center for Artificial Organs and Transplantation (ICAOT), 4

**L**

Life table patency rates See Patency
Limb salvage, 25–32, 53, 54
Limbs, vascular grafts in
  Dacron grafts, 16–24
  use of glutaraldehyde stabilizer, 50–59, 300
  patency, 22
  polytetrafluoroethylene grafts, 25–32
Lipid imbibition
  umbilical cord vein graft, 54
Long-term morphological changes, 50–59

**M**

Macrophages, 186, 199–217
Mandril-grown grafts, 103–105
INDEX 347

Materials, vascular graft
innovative, 293–305, 293, 294 (tables) See also Dacron; Polydioxanone; Polydimethylsiloxane; Polysters; Polyethylene, low density; Polylactin 910; Polylglycolic acid; Polytetrafluoroethylene; Polyurethane, bioelectric; Silicone rubber; Teflon®

Medical Device Amendment to the Food, Drug, and Cosmetic Act (1976), 284

Mesh reinforcing of vascular grafts, 51, 85–102

Microanatomy
Dacron grafts, 16–24
Morphological changes
umbilical cord vein graft, 50–59
Mullen Burst Test
ASTM Standard D 3786–80a: 116
Myofibroblasts, 199–215

N
Neointima, 157, 160, 172 See also Endothelialization

O
Occlusion See Patency
Ovine grafts, 105

P
Patency
acellular matrix grafts, 227–229
comparison various graft types, 22 (table)
coronary artery bypass grafts, 47 (table)
Dacron grafts, 16–24, 191–192
effect of antithrombotic drugs, 192 (table)
effect of gas/plasma discharge treatment, 148–154
effect of glutaraldehyde stabilizer, 53, 297–298, 301
polytetrafluoroethylene grafts, 25–32
seeded/non-seeded grafts, 192 (table)
Performance, vascular grafts, 278–305
Plasma discharge treatment, 137–155, 141 (diagram)
Platelets
adhesion, 173 (table)
growth factors, 209
survival in endothelial cell seeded grafts, 38–39
Polydimethylsiloxane (PDMS), 172–176
Polydioxanone, 209, 214
Polyesters See also Dacron vascular grafts
chemical resistance of, 72 (table)
fabrication of, 71–79
history of use in vascular grafts, 11–15
testing of, 77, 80–81
water porosity, 122–136
Polyethylene, low density (LDPE), 172–176
Polyethylene terephthalate See Dacron vascular grafts
Polylactin 910, 209–214
Polyglycolic acid, 200–211
Polytetrafluoroethylene, expanded (PTFE) vascular grafts
endurance, 108–121
use in limb arterial grafts, 25–32
physical properties, 82–94
dynamic, 92 (table)
static, 92 (table)
seeded grafts, 36, 39
testing of, 84–93, 108–121, 172–175
Polyurethane, bioelectric (BEP), 61–66
Porosity
- effect on polymer strength, 111
- and electrochemical laws, 291–293
- gas discharge treatment, 143 (table)
- water testing, 85, 122–136, 124 (diagram)

Preservation, vascular grafts, 156–165
- various methods, 163 (table)

Pressure equivalent electroosmosis, 292–293

Prostacyclin, 38, 193–195, 202

Prostaglandins, 193–195

Prostheses See Arteries; Materials, vascular grafts; Veins

Pseudointima, 180–188 See also Endothelialization

Pyrogens
- synthetic grafts, 242–249

R

Radio frequency glow discharge treatment, 137–155

Reconstructive arterial surgery See Surgery, vascular

Reinforcing of vascular grafts, 21, 51, 85–102

Regulation, FDA, 5–9

Replamineform fabrication, 60–67

Research, history of, 253–277

Retrieval, vascular grafts, 158–161, 265–276

Revascularization, lower limb, 50–59, 181–182, 300 See also Surgery, vascular

S

Safety and efficacy
- proof for FDA, 284–289

Sea urchin spines, 60–67

SDS-polyacrylamide gel electrophoresis, 183

Seeded grafts, 33–43, 189–196

patency, 192 (table)

thrombus formation, 192 (table)

Silicone rubber vascular grafts 61–66, 294

Sintering, 87–89

Small artery grafts See Small caliber grafts

Small caliber grafts (see others)
- acellular vascular matrix, 219–235
- collagen, 293–304
- FDA regulation of, 6–7
- gas/plasma discharge treatment, 137–155
- history of development, 13–14
- innovative materials, 290–305
- replamineform fabrication, 60–67
- seeded Dacron grafts, 189–196
- surface modification of, 137–155

Sodium dodecyl sulfate (SDS), 226

Species selection, 169–178 See also Animal experimental models

Spectroscopy
- electron, 140
- infrared, 99–101

Stabilizers See Carbodiimide stabilizer; Glutaraldehyde stabilizer

Standards development, 5–7, 253–290, 304

FDA procedures, 285–289

parameters for graft applications, 281

Sterility
- effect on thrombus formation, 244 (table)

synthetic grafts, 236–249

Sterilization techniques, 239–241, 239 (table)

Strength, vascular grafts, 108–121
- burst tests, 86, 93, 203
- fatigue tests, 117–119
- pressure tests, 116
- MPa, 110
- sintering, 87–89
- suture retention, 86–87, 91–92
INDEX 349

tension tests, 85, 92–93, 115
yarn, 110
Surface modification, 137–155
and biological response, 138 (table)
Surgery, vascular, 11–15
cardiac, 42–49
Suture retention, 86–87, 91–92
Synthetic prostheses See Materials, vascular graft

T
Tanning agents, 296 See also Glutaraldehyde stabilizer; Carbodiimide stabilizer
Teflon, 172–176, 294, 295
Tensile strength tests, 85, 92–93
ASTM Standard D 638: 115
Tests of vascular grafts See also
ASTM Standards
biocompatibility, 169–178
biological, 81 (table)
blood flow, 146–147
burst, 92–93, 116, 203
contact angle measurement, 100, 103
critical surface tensions, 100
fatigue, 117–119
porosity, 85, 122–136
pressure, 116, 213
pulse cycle, 213–214
quality assurance, 81 (table)
tension, 85, 92–93, 115
Thromboxane, 193–195
Thromboxane synthase inhibitors 193–195
Thrombus/embolus formation
acellular vascular matrix grafts, 229–231
biosynthetic grafts, 97
electrochemical laws, 290–305
endothelial cell seeded grafts, 33–43, 191–195
fluoropolymer coatings, 147
in glutaraldehyde stabilized grafts, 55
and graft surface modification, 147–154
microemboli, 147, 149
and preventative drugs, 47–49, 192–194, 230
in vitro vs in vivo, 148–149, 172–176
and sterility, 244
Triton X-100, 226

V
Vascular surgery See Surgery, vascular
Veins, 33–43
external jugular, 190–195
saphenous, 13–14, 44–49
umbilical cord, 50–59, 297
Velouring of graft material, 19, 123
effect on patency, 22 (table)
effect on water porosity, 129

W
Warfarin, 48–49
Warp knitting, 19, 74–78
and life table patency, 22
Water porosity, 122–136
Weft knitting, 18, 74–78
and life table patency, 22

Y
Yarn
spinning of, 73 (diagram)
strength, 110–111